<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36830735</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>Complement as a Biomarker for Systemic Lupus Erythematosus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">367</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom13020367</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) is a disease of immune complex deposition; therefore, complement plays a vital role in the pathogenesis of SLE. In general, complement levels in blood and complement deposition in histological tests are used for the management of SLE. Thus, the evaluation of complement status can be useful in the diagnosis of SLE, assessment of disease activity, and prediction of treatment response and prognosis. In addition, novel complement biomarkers, such as split products and cell-bound complement activation products, are considered to be more sensitive than traditional complement markers, such as serum C3 and C4 levels and total complement activity (CH50), which become more widely used. In this review, we report the complement testing in the management of SLE over the last decade and summarize their utility.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ayano</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cancer Stem Cell Research, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horiuchi</LastName><ForeName>Takahiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Kyushu University Beppu Hospital, 4546 Tsurumibaru, Tsurumi, Beppu 874-0838, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9007-36-7</RegistryNumber><NameOfSubstance UI="D003165">Complement System Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003165" MajorTopicYN="N">Complement System Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cell-bound complement activation product</Keyword><Keyword MajorTopicYN="N">complement</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">serological activity</Keyword><Keyword MajorTopicYN="N">split product</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36830735</ArticleId><ArticleId IdType="pmc">PMC9953581</ArticleId><ArticleId IdType="doi">10.3390/biom13020367</ArticleId><ArticleId IdType="pii">biom13020367</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fanouriakis A., Tziolos N., Bertsias G., Boumpas D.T. Update in the Diagnosis and Management of Systemic Lupus Erythematosus. Ann. Rheum. Dis. 2021;80:14&#x2013;25. doi: 10.1136/annrheumdis-2020-218272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218272</ArticleId><ArticleId IdType="pubmed">33051219</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan L., Lu M.P., Wang J.H., Xu M., Yang S.R. Immunological Pathogenesis and Treatment of Systemic Lupus Erythematosus. World J. Pediatr. 2020;16:19&#x2013;30. doi: 10.1007/s12519-019-00229-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12519-019-00229-3</ArticleId><ArticleId IdType="pmc">PMC7040062</ArticleId><ArticleId IdType="pubmed">30796732</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;rner T., Furie R. Novel Paradigms in Systemic Lupus Erythematosus. Lancet. 2019;393:2344&#x2013;2358. doi: 10.1016/S0140-6736(19)30546-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)30546-X</ArticleId><ArticleId IdType="pubmed">31180031</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven R.F., Mosca M., Bertsias G., Isenberg D., Kuhn A., Lerstr&#xf8;m K., Aringer M., Bootsma H., Boumpas D., Bruce I.N., et al. Treat-to-Target in Systemic Lupus Erythematosus: Recommendations from an International Task Force. Ann. Rheum. Dis. 2014;73:958&#x2013;967. doi: 10.1136/annrheumdis-2013-205139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205139</ArticleId><ArticleId IdType="pubmed">24739325</ArticleId></ArticleIdList></Reference><Reference><Citation>Capecchi R., Puxeddu I., Pratesi F., Migliorini P. New Biomarkers in SLE: From Bench to Bedside. Rheumatology. 2020;59:V12&#x2013;V18. doi: 10.1093/rheumatology/keaa484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa484</ArticleId><ArticleId IdType="pmc">PMC7719038</ArticleId><ArticleId IdType="pubmed">32911542</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez L.A., Ugarte-Gil M.F., Alarc&#xf3;n G.S. Systemic Lupus Erythematosus: The Search for the Ideal Biomarker. Lupus. 2021;30:181&#x2013;203. doi: 10.1177/0961203320979051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320979051</ArticleId><ArticleId IdType="pubmed">33307987</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H., Nagafuchi Y., Fujio K. Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus. Biomolecules. 2021;11:928. doi: 10.3390/biom11070928.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11070928</ArticleId><ArticleId IdType="pmc">PMC8301935</ArticleId><ArticleId IdType="pubmed">34206696</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein A., Alexander R.V., Zack D.J. A Review of Complement Activation in SLE. Curr. Rheumatol. Rep. 2021;23:4&#x2013;11. doi: 10.1007/s11926-021-00984-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-021-00984-1</ArticleId><ArticleId IdType="pmc">PMC7875837</ArticleId><ArticleId IdType="pubmed">33569681</ArticleId></ArticleIdList></Reference><Reference><Citation>Leffler J., Bengtsson A.A., Blom A.M. The Complement System in Systemic Lupus Erythematosus: An Update. Ann. Rheum. Dis. 2014;73:1601&#x2013;1606. doi: 10.1136/annrheumdis-2014-205287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-205287</ArticleId><ArticleId IdType="pubmed">24845390</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma M., Vignesh P., Tiewsoh K., Rawat A. Revisiting the Complement System in Systemic Lupus Erythematosus. Expert Rev. Clin. Immunol. 2020;16:397&#x2013;408. doi: 10.1080/1744666X.2020.1745063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2020.1745063</ArticleId><ArticleId IdType="pubmed">32228236</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll M.C. The Lupus Paradox. Nat. Genet. 1998;19:3&#x2013;4. doi: 10.1038/ng0598-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0598-3</ArticleId><ArticleId IdType="pubmed">9590274</ArticleId></ArticleIdList></Reference><Reference><Citation>Macedo A.C.L., Isaac L. Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway. Front. Immunol. 2016;7:55. doi: 10.3389/fimmu.2016.00055.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00055</ArticleId><ArticleId IdType="pmc">PMC4764694</ArticleId><ArticleId IdType="pubmed">26941740</ArticleId></ArticleIdList></Reference><Reference><Citation>Felten R., Scherlinger M., Mertz P., Chasset F., Arnaud L. New Biologics and Targeted Therapies in Systemic Lupus: From New Molecular Targets to New Indications. A Systematic Review. Jt. Bone Spine. 2023;90:105523. doi: 10.1016/j.jbspin.2023.105523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbspin.2023.105523</ArticleId><ArticleId IdType="pubmed">36623799</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan T.M., Yung S., Yap D.Y.H. A Review of Advances in the Understanding of Lupus Nephritis Pathogenesis as a Basis for Emerging Therapies. F1000Research. 2020;9:905. doi: 10.12688/f1000research.22438.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.22438.1</ArticleId><ArticleId IdType="pmc">PMC7405261</ArticleId><ArticleId IdType="pubmed">32789005</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulvihill E., Ardoin S., Thompson S.D., Zhou B., Yu G.R., King E., Singer N., Levy D.M., Brunner H., Wu Y.L., et al. Elevated Serum Complement Levels and Higher Gene Copy Number of Complement C4B Are Associated with Hypertension and Effective Response to Statin Therapy in Childhood-Onset Systemic Lupus Erythematosus (SLE) Lupus Sci. Med. 2019;6:e000333. doi: 10.1136/lupus-2019-000333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2019-000333</ArticleId><ArticleId IdType="pmc">PMC6687033</ArticleId><ArticleId IdType="pubmed">31448126</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y.L., Higgins G.C., Rennebohm R.M., Chung E.K., Yang Y., Zhou B., Nagaraja H.N., Birmingham D.J., Rovin B.H., Hebert L.A., et al. Three distinct profiles of serum complement C4 proteins in pediatric systemic lupus erythematosus (SLE) patients: Tight associations of complement C4 and C3 protein levels in SLE but not in healthy subjects. Adv. Exp. Med. Biol. 2006;586:227&#x2013;247. doi: 10.1007/0-387-34134-X_16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/0-387-34134-X_16</ArticleId><ArticleId IdType="pubmed">16893076</ArticleId></ArticleIdList></Reference><Reference><Citation>Margery-Muir A.A., Bundell C., Wetherall J.D., Whidborne R., Martinez P., Groth D.M. Insights on the Relationship between Complement Component C4 Serum Concentrations and C4 Gene Copy Numbers in a Western Australian Systemic Lupus Erythematosus Cohort. Lupus. 2018;27:1687&#x2013;1696. doi: 10.1177/0961203318787039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318787039</ArticleId><ArticleId IdType="pubmed">30041577</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundtoft C., Pucholt P., Martin M., Bianchi M., Lundstr&#xf6;m E., Eloranta M.L., Sandling J.K., Sj&#xf6;wall C., J&#xf6;nsen A., Gunnarsson I., et al. Complement C4 Copy Number Variation Is Linked to SSA/Ro and SSB/La Autoantibodies in Systemic Inflammatory Autoimmune Diseases. Arthritis Rheumatol. 2022;74:1440&#x2013;1450. doi: 10.1002/art.42122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42122</ArticleId><ArticleId IdType="pmc">PMC9543510</ArticleId><ArticleId IdType="pubmed">35315244</ArticleId></ArticleIdList></Reference><Reference><Citation>Savelli S.L., Roubey R.A.S., Kitzmiller K.J., Zhou D., Nagaraja H.N., Mulvihill E., Barbar-Smiley F., Ardoin S.P., Wu Y.L., Yu C.Y. Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) among Patients with Antiphospholipid Antibodies (APL) Front. Immunol. 2019;10:885. doi: 10.3389/fimmu.2019.00885.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00885</ArticleId><ArticleId IdType="pmc">PMC6514053</ArticleId><ArticleId IdType="pubmed">31134052</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M., Costenbader K., Daikh D., Brinks R., Mosca M., Ramsey-Goldman R., Smolen J.S., Wofsy D., Boumpas D.T., Kamen D.L., et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71:1400&#x2013;1412. doi: 10.1002/art.40930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40930</ArticleId><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg M.C. Updating the American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus Erythematosus. Arthritis Rheum. 1997;40:1725. doi: 10.1002/art.1780400928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M., Orbai A.M., Alarc&#xf5;n G.S., Gordon C., Merrill J.T., Fortin P.R., Bruce I.N., Isenberg D., Wallace D.J., Nived O., et al. Derivation and Validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum. 2012;64:2677&#x2013;2686. doi: 10.1002/art.34473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Estel G.J., Ugarte-Gil M.F., Harvey G.B., Wojdyla D., Quintana R., Saurit V., Soriano E.R., Bonfa E., Massardo L., Cardiel M., et al. Applying the 2019 EULAR/ACR Lupus Criteria to Patients from an Established Cohort: A Latin American Perspective. RMD Open. 2020;6:e001097. doi: 10.1136/rmdopen-2019-001097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2019-001097</ArticleId><ArticleId IdType="pmc">PMC6999682</ArticleId><ArticleId IdType="pubmed">31958284</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson S.R., Brinks R., Costenbader K.H., Daikh D., Mosca M., Ramsey-Goldman R., Smolen J.S., Wofsy D., Boumpas D.T., Kamen D.L., et al. Performance of the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in Early Disease, across Sexes and Ethnicities. Ann. Rheum. Dis. 2020;79:1333&#x2013;1339. doi: 10.1136/annrheumdis-2020-217162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217162</ArticleId><ArticleId IdType="pubmed">32816709</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung Y.K., Ho L.Y., Lee C., To C.H., Mok C.C. Validation of the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in ANA-Positive Chinese Patients. Ther. Adv. Musculoskelet. Dis. 2022;14:1759720X221100300. doi: 10.1177/1759720X221100300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1759720X221100300</ArticleId><ArticleId IdType="pmc">PMC9150246</ArticleId><ArticleId IdType="pubmed">35651982</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema I.M., Wilhelmus S., Alpers C.E., Bruijn J.A., Colvin R.B., Cook H.T., D&#x2019;Agati V.D., Ferrario F., Haas M., Jennette J.C., et al. Revision of the International Society of Nephrology/Renal Pathology Society Classification for Lupus Nephritis: Clarification of Definitions, and Modified National Institutes of Health Activity and Chronicity Indices. Kidney Int. 2018;93:789&#x2013;796. doi: 10.1016/j.kint.2017.11.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.11.023</ArticleId><ArticleId IdType="pubmed">29459092</ArticleId></ArticleIdList></Reference><Reference><Citation>Weening J.J., D&#x2019;Agati V.D., Schwartz M.M., Seshan S.V., Alpers C.E., Appel G.B., Balow J.E., Bruijn J.A., Cook T., Ferrario F., et al. The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. Kidney Int. 2004;65:521&#x2013;530. doi: 10.1111/j.1523-1755.2004.00443.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2004.00443.x</ArticleId><ArticleId IdType="pubmed">14717922</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickering M.C., D&#x2019;agati V.D., Nester C.M., Smith R.J., Haas M., Appel G.B., Alpers C.E., Bajema I.M., Bedrosian C., Braun M., et al. C3 Glomerulopathy: Consensus Report. Kidney Int. 2013;84:1079&#x2013;1089. doi: 10.1038/ki.2013.377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2013.377</ArticleId><ArticleId IdType="pmc">PMC3842953</ArticleId><ArticleId IdType="pubmed">24172683</ArticleId></ArticleIdList></Reference><Reference><Citation>Sethi S., Haas M., Markowitz G.S., D&#x2019;Agati V.D., Rennke H.G., Jennette J.C., Bajema I.M., Alpers C.E., Chang A., Cornell L.D., et al. Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. J. Am. Soc. Nephrol. 2016;27:1278&#x2013;1287. doi: 10.1681/ASN.2015060612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2015060612</ArticleId><ArticleId IdType="pmc">PMC4849835</ArticleId><ArticleId IdType="pubmed">26567243</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds J.A., McCarthy E.M., Haque S., Ngamjanyaporn P., Sergeant J.C., Lee E., Lee E., Kilfeather S.A., Parker B., Bruce I.N. Cytokine Profiling in Active and Quiescent SLE Reveals Distinct Patient Subpopulations. Arthritis Res. Ther. 2018;9:173. doi: 10.1186/s13075-018-1666-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-018-1666-0</ArticleId><ArticleId IdType="pmc">PMC6085716</ArticleId><ArticleId IdType="pubmed">30092845</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki T., Doi H., Tsuji H., Tabuchi Y., Hashimoto M., Kitagori K., Akizuki S., Murakami K., Nakashima R., Yoshifuji H., et al. Phenotypic Landscape of Systemic Lupus Erythematosus: An Analysis of the Kyoto Lupus Cohort. Mod. Rheumatol. 2022;32:571&#x2013;576. doi: 10.1093/mr/roab020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/mr/roab020</ArticleId><ArticleId IdType="pubmed">34894258</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung J.Y., Lee H.Y., Lee E., Kim H.A., Yoon D., Suh C.H. Three Clinical Clusters Identified through Hierarchical Cluster Analysis Using Initial Laboratory Findings in Korean Patients with Systemic Lupus Erythematosus. J. Clin. Med. 2022;11:2406. doi: 10.3390/jcm11092406.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11092406</ArticleId><ArticleId IdType="pmc">PMC9105234</ArticleId><ArticleId IdType="pubmed">35566532</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie W., Xiao Z., Xu J., Hong G., Xu X., Zhang Y., Zhang X. The Clinical Characteristics of Low C4 Alone in Patients with Systemic Lupus Erythematosus. Clin. Rheumatol. 2021;40:793&#x2013;796. doi: 10.1007/s10067-020-05367-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-05367-y</ArticleId><ArticleId IdType="pubmed">32856201</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishizaki J., Saito K., Nawata M., Mizuno Y., Tokunaga M., Sawamukai N., Tamura M., Hirata S., Yamaoka K., Hasegawa H., et al. Low Complements and High Titre of Anti-Sm Antibody as Predictors of Histopathologically Proven Silent Lupus Nephritis without Abnormal Urinalysis in Patients with Systemic Lupus Erythematosus. Rheumatology. 2015;54:405&#x2013;412. doi: 10.1093/rheumatology/keu343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keu343</ArticleId><ArticleId IdType="pubmed">25183834</ArticleId></ArticleIdList></Reference><Reference><Citation>Asano T., Ito H., Kariya Y., Hoshi K., Yoshihara A., Ugawa Y., Sekine H., Hirohata S., Yamaguchi Y., Sato S., et al. Evaluation of Blood-Brain Barrier Function by Quotient Alpha2 Macroglobulin and Its Relationship with Interleukin-6 and Complement Component 3 Levels in Neuropsychiatric Systemic Lupus Erythematosus. PLoS ONE. 2017;12:e0186414. doi: 10.1371/journal.pone.0186414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0186414</ArticleId><ArticleId IdType="pmc">PMC5643139</ArticleId><ArticleId IdType="pubmed">29036223</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D.Y., Huang Y.H., Chen Y.M., Chen J.J.W., Yang T.Y., Chang G.C., Tang K.T. ANA Positivity and Complement Level in Pleural Fluid Are Potential Diagnostic Markers in Discriminating Lupus Pleuritis from Pleural Effusion of Other Aetiologies. Lupus Sci. Med. 2021;8:e000562. doi: 10.1136/lupus-2021-000562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000562</ArticleId><ArticleId IdType="pmc">PMC8596033</ArticleId><ArticleId IdType="pubmed">34785570</ArticleId></ArticleIdList></Reference><Reference><Citation>Touma Z., Urowitz M.B., Gladman D.D. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Website. J. Rheumatol. 2013;40:733. doi: 10.3899/jrheum.130030.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.130030</ArticleId><ArticleId IdType="pubmed">23637378</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg D.A., Rahman A., Allen E., Farewell V., Akil M., Bruce I.N., D&#x2019;Cruz D., Griffiths B., Khamashta M., Maddison P., et al. BILAG 2004. Development and Initial Validation of an Updated Version of the British Isles Lupus Assessment Group&#x2019;s Disease Activity Index for Patients with Systemic Lupus Erythematosus. Rheumatology. 2005;44:902&#x2013;906. doi: 10.1093/rheumatology/keh624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keh624</ArticleId><ArticleId IdType="pubmed">15814577</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesus D., Matos A., Henriques C., Zen M., Larosa M., Iaccarino L., Da Silva J.A.P., Doria A., In&#xea;s L.S. Derivation and Validation of the SLE Disease Activity Score (SLE-DAS): A New SLE Continuous Measure with High Sensitivity for Changes in Disease Activity. Ann. Rheum. Dis. 2018;2000:365&#x2013;371. doi: 10.1136/annrheumdis-2018-214502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214502</ArticleId><ArticleId IdType="pubmed">30626657</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklyn K., Lau C.S., Navarra S.V., Louthrenoo W., Lateef A., Hamijoyo L., Wahono C.S., Chen S.L., Jin O., Morton S., et al. Definition and Initial Validation of a Lupus Low Disease Activity State (LLDAS) Ann. Rheum. Dis. 2016;75:1615&#x2013;1621. doi: 10.1136/annrheumdis-2015-207726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207726</ArticleId><ArticleId IdType="pubmed">26458737</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven R.F., Bertsias G., Doria A., Isenberg D., Morand E., Petri M.A., Pons-Estel B.A., Rahman A., Ugarte-Gil M.F., Voskuyl A., et al. 2021 DORIS Definition of Remission in SLE: Final Recommendations from an International Task Force. Lupus Sci. Med. 2021;8:e000538. doi: 10.1136/lupus-2021-000538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000538</ArticleId><ArticleId IdType="pmc">PMC8614136</ArticleId><ArticleId IdType="pubmed">34819388</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven R.F., Voskuyl A., Bertsias G., Aranow C., Aringer M., Arnaud L., Askanase A., Bal&#xe1;&#x17e;ov&#xe1; P., Bonfa E., Bootsma H., et al. A Framework for Remission in SLE: Consensus Findings from a Large International Task Force on Definitions of Remission in SLE (DORIS) Ann. Rheum. Dis. 2017;76:554&#x2013;561. doi: 10.1136/annrheumdis-2016-209519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-209519</ArticleId><ArticleId IdType="pubmed">27884822</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A., Kostopoulou M., Alunno A., Aringer M., Bajema I., Boletis J.N., Cervera R., Doria A., Gordon C., Govoni M., et al. 2019 Update of the EULAR Recommendations for the Management of Systemic Lupus Erythematosus. Ann. Rheum. Dis. 2019;78:736&#x2013;745. doi: 10.1136/annrheumdis-2019-215089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok C.C., Hamijoyo L., Kasitanon N., Chen D.Y., Chen S., Yamaoka K., Oku K., Li M.T., Zamora L., Bae S.C., et al. The Asia-Pacific League of Associations for Rheumatology Consensus Statements on the Management of Systemic Lupus Erythematosus. Lancet Rheumatol. 2021;3:e517&#x2013;e531. doi: 10.1016/S2665-9913(21)00009-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00009-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson C., Henderson R.B., Jones-Leone A.R., Flint S.M., Lennon M., Levy R.A., Ji B., Bass D.L., Roth D. The Role of Baseline BLyS Levels and Type 1 Interferon-Inducible Gene Signature Status in Determining Belimumab Response in Systemic Lupus Erythematosus: A Post Hoc Meta-Analysis. Arthritis Res. Ther. 2020;22:1&#x2013;11. doi: 10.1186/s13075-020-02177-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-020-02177-0</ArticleId><ArticleId IdType="pmc">PMC7197114</ArticleId><ArticleId IdType="pubmed">32366280</ArticleId></ArticleIdList></Reference><Reference><Citation>Vital E.M., Merrill J.T., Morand E.F., Furie R.A., Bruce I.N., Tanaka Y., Manzi S., Kalunian K.C., Kalyani R.N., Streicher K., et al. Anifrolumab Efficacy and Safety by Type I Interferon Gene Signature and Clinical Subgroups in Patients with SLE: Post Hoc Analysis of Pooled Data from Two Phase III Trials. Ann. Rheum. Dis. 2022;81:951&#x2013;961. doi: 10.1136/annrheumdis-2021-221425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221425</ArticleId><ArticleId IdType="pmc">PMC9213795</ArticleId><ArticleId IdType="pubmed">35338035</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth D.A., Thompson A., Tang Y., Hammer A.E., Molta C.T., Gordon D. Elevated BLyS Levels in Patients with Systemic Lupus Erythematosus: Associated Factors and Responses to Belimumab. Lupus. 2016;25:346&#x2013;354. doi: 10.1177/0961203315604909.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203315604909</ArticleId><ArticleId IdType="pmc">PMC4785993</ArticleId><ArticleId IdType="pubmed">26385220</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubbard E.L., Pisetsky D.S., Lipsky P.E. Anti-RNP Antibodies Are Associated with the Interferon Gene Signature but Not Decreased Complement Levels in SLE. Ann. Rheum. Dis. 2022;81:632&#x2013;643. doi: 10.1136/annrheumdis-2021-221662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221662</ArticleId><ArticleId IdType="pubmed">35115332</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J., Gu J., Su Y., Li Y., Li X., Xiong C., Cao H., Quasny H., Chu M., Curtis P., et al. Efficacy of Belimumab in Patients with Systemic Lupus Erythematosus from North East Asia: Results of Exploratory Subgroup Analyses. Mod. Rheumatol. 2022:roac076. doi: 10.1093/mr/roac076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/mr/roac076</ArticleId><ArticleId IdType="pubmed">36208293</ArticleId></ArticleIdList></Reference><Reference><Citation>Gensous N., Marti A., Barnetche T., Blanco P., Lazaro E., Seneschal J., Truchetet M.E., Duffau P., Richez C. Predictive Biological Markers of Systemic Lupus Erythematosus Flares: A Systematic Literature Review. Arthritis Res. Ther. 2017;19:238. doi: 10.1186/s13075-017-1442-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-017-1442-6</ArticleId><ArticleId IdType="pmc">PMC5655881</ArticleId><ArticleId IdType="pubmed">29065901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostopoulou M., Ugarte-Gil M.F., Pons-Estel B., van Vollenhoven R.F., Bertsias G. The Association between Lupus Serology and Disease Outcomes: A Systematic Literature Review to Inform the Treat-to-Target Approach in Systemic Lupus Erythematosus. Lupus. 2022;31:307&#x2013;318. doi: 10.1177/09612033221074580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221074580</ArticleId><ArticleId IdType="pubmed">35067068</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiman A.J., Gladman D.D., Iba&#xf1;ez D., Urowitz M.B. Prolonged Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Frequency and Outcome. J. Rheumatol. 2010;37:1822&#x2013;1827. doi: 10.3899/jrheum.100007.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.100007</ArticleId><ArticleId IdType="pubmed">20595281</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti F., Ceccarelli F., Perricone C., Miranda F., Truglia S., Massaro L., Pacucci V.A., Conti V., Bartosiewicz I., Spinelli F.R., et al. Flare, Persistently Active Disease, and Serologically Active Clinically Quiescent Disease in Systemic Lupus Erythematosus: A 2-Year Follow-Up Study. PLoS ONE. 2012;7:e45934. doi: 10.1371/journal.pone.0045934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0045934</ArticleId><ArticleId IdType="pmc">PMC3448702</ArticleId><ArticleId IdType="pubmed">23029327</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H., Mu L., Zhang Z., Gao D., Hao Y., Zhou W. Treatments and Outcomes in Chinese Patients with Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: A Retrospective Observational Study. Arthritis Res. Ther. 2021;23:275. doi: 10.1186/s13075-021-02641-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-021-02641-5</ArticleId><ArticleId IdType="pmc">PMC8556984</ArticleId><ArticleId IdType="pubmed">34715915</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyawaki Y., Sada K., Asano Y., Hayashi K., Yamamura Y., Hiramatsu S., Ohashi K., Morishita M., Watanabe H., Matsumoto Y., et al. Progressive Reduction of Serum Complement Levels: A Risk Factor for Relapse in Patients with Hypocomplementemia in Systemic Lupus Erythematosus. Lupus. 2018;27:2093&#x2013;2100. doi: 10.1177/0961203318804892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318804892</ArticleId><ArticleId IdType="pubmed">30309286</ArticleId></ArticleIdList></Reference><Reference><Citation>Ligtenberg G., Arends S., Stegeman C.A., De Leeuw K. Predictors of Renal Flares and Long-Term Renal Outcome in Patients with Lupus Nephritis: Results from Daily Clinical Practice. Clin. Exp. Rheumatol. 2022;40:33&#x2013;38. doi: 10.55563/clinexprheumatol/c58c39.</Citation><ArticleIdList><ArticleId IdType="doi">10.55563/clinexprheumatol/c58c39</ArticleId><ArticleId IdType="pubmed">33822705</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Huang S., Chen T., Liang D., Yang J., Zeng C., Li X., Xie G., Liu Z. Machine Learning for Prediction and Risk Stratification of Lupus Nephritis Renal Flare. Am. J. Nephrol. 2021;52:152&#x2013;160. doi: 10.1159/000513566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000513566</ArticleId><ArticleId IdType="pubmed">33744876</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi G.M., Maggiore U., Peyronel F., Fenaroli P., Delsante M., Benigno G.D., Gianfreda D., Urban M.L., Manna Z., Arend L.J., et al. Persistent Isolated C3 Hypocomplementemia as a Strong Predictor of End-Stage Kidney Disease in Lupus Nephritis. Kidney Int. Rep. 2022;7:2647&#x2013;2656. doi: 10.1016/j.ekir.2022.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2022.09.012</ArticleId><ArticleId IdType="pmc">PMC9727529</ArticleId><ArticleId IdType="pubmed">36506236</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrera-Vargas A., Quintanar-Mart&#xed;nez M., Merayo-Chalico J., Alcocer-Varela J., G&#xf3;mez-Mart&#xed;n D. Risk Factors for Systemic Lupus Erythematosus Flares in Patients with End-Stage Renal Disease: A Case-Control Study. Rheumatology. 2016;55:429&#x2013;435. doi: 10.1093/rheumatology/kev349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kev349</ArticleId><ArticleId IdType="pubmed">26396262</ArticleId></ArticleIdList></Reference><Reference><Citation>Aso K., Kono M., Kono M., Watanabe T., Shimizu Y., Ogata Y., Fujieda Y., Kato M., Oku K., Amengual O., et al. Low C4 as a Risk Factor for Severe Neuropsychiatric Flare in Patients with Systemic Lupus Erythematosus. Lupus. 2020;29:1238&#x2013;1247. doi: 10.1177/0961203320938453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320938453</ArticleId><ArticleId IdType="pubmed">32635880</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Huang G., Lin J., Lin Q., Zheng K., Hu S., Zheng S., Du G., Matucci-Cerinic M., Furst D.E., et al. Predictive Model of Risk and Severity of Enteritis in Systemic Lupus Erythematosus. Lupus. 2022;31:1226&#x2013;1236. doi: 10.1177/09612033221110743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221110743</ArticleId><ArticleId IdType="pubmed">35750508</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., He Q., Luo M., Gou Y., Jiang D., Zheng X., Yan G., He F. Clinical Features of Lupus Enteritis: A Single-Center Retrospective Study. Orphanet J. Rare Dis. 2021;16:396. doi: 10.1186/s13023-021-02044-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-021-02044-4</ArticleId><ArticleId IdType="pmc">PMC8474739</ArticleId><ArticleId IdType="pubmed">34565417</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida Y., Omoto T., Kohno H., Tokunaga T., Kuranobu T., Yukawa K., Watanabe H., Oi K., Sugimoto T., Mokuda S., et al. Lower CH50 as a Predictor for Intractable or Recurrent Lupus Enteritis: A Retrospective Observational Study. Mod. Rheumatol. 2021;31:643&#x2013;648. doi: 10.1080/14397595.2020.1812871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14397595.2020.1812871</ArticleId><ArticleId IdType="pubmed">32815450</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H., Chen Y., Zhao L., Liu Y., Wang Y., Tian X., Zhang W., Li M., Zhao Y., Leng X., et al. Clinical Characteristics and Outcomes of Lupus Myocarditis: A Retrospective Case Control Study in Chinese Patients. Clin. Exp. Rheumatol. 2022;40:1650&#x2013;1656. doi: 10.55563/clinexprheumatol/ixcj8a.</Citation><ArticleIdList><ArticleId IdType="doi">10.55563/clinexprheumatol/ixcj8a</ArticleId><ArticleId IdType="pubmed">35485421</ArticleId></ArticleIdList></Reference><Reference><Citation>Trendelenburg M. Autoantibodies against Complement Component C1q in Systemic Lupus Erythematosus. Clin. Transl. Immunol. 2021;10:e1279. doi: 10.1002/cti2.1279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1279</ArticleId><ArticleId IdType="pmc">PMC8082710</ArticleId><ArticleId IdType="pubmed">33968409</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandholm K., Persson B., Skattum L., Eggertsen G., Nyman D., Gunnarsson I., Svenungson E., Nilsson B., Ekdahl K.N. Evaluation of a Novel Immunoassay for Quantification of C1q for Clinical Diagnostic Use. Front. Immunol. 2019;10:7. doi: 10.3389/fimmu.2019.00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00007</ArticleId><ArticleId IdType="pmc">PMC6357986</ArticleId><ArticleId IdType="pubmed">30740097</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y., Song D., Wu L.H., Yu F., Zhao M.H. Serum Levels and Renal Deposition of C1q Complement Component and Its Antibodies Reflect Disease Activity of Lupus Nephritis. BMC Nephrol. 2013;14:63. doi: 10.1186/1471-2369-14-63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2369-14-63</ArticleId><ArticleId IdType="pmc">PMC3616847</ArticleId><ArticleId IdType="pubmed">23510032</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu B., Zhang Y.M., Yang Y.W., Liu Y.S., Feng J.F. Diagnostic Performance of Serum Cystatin C and Complement Component 1q in Lupus Nephritis. Arthritis Res. Ther. 2019;21:267. doi: 10.1186/s13075-019-2065-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-019-2065-x</ArticleId><ArticleId IdType="pmc">PMC6894121</ArticleId><ArticleId IdType="pubmed">31801580</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim A.H.J., Strand V., Sen D.P., Fu Q., Mathis N.L., Schmidt M.J., Bruchas R.R., Staten N.R., Olson P.K., Stiening C.M., et al. Association of Blood Concentrations of Complement Split Product IC3b and Serum C3 with Systemic Lupus Erythematosus Disease Activity. Arthritis Rheumatol. 2019;71:420&#x2013;430. doi: 10.1002/art.40747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40747</ArticleId><ArticleId IdType="pmc">PMC6393208</ArticleId><ArticleId IdType="pubmed">30294950</ArticleId></ArticleIdList></Reference><Reference><Citation>Troldborg A., Jensen L., Deleuran B., Stengaard-Pedersen K., Thiel S., Jensenius J.C. The C3dg Fragment of Complement Is Superior to Conventional C3 as a Diagnostic Biomarker in Systemic Lupus Erythematosus. Front. Immunol. 2018;9:581. doi: 10.3389/fimmu.2018.00581.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00581</ArticleId><ArticleId IdType="pmc">PMC5879092</ArticleId><ArticleId IdType="pubmed">29632534</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganguly S., Majumder S., Kumar S., Gupta R., Muhammed H., Shobha V., Aggarwal A., Misra R. Urinary C3d Is Elevated in Patients with Active Lupus Nephritis and a Fall in Its Level after 3 Months Predicts Response at 6 Months on Follow Up. Lupus. 2020;29:1800&#x2013;1806. doi: 10.1177/0961203320950019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320950019</ArticleId><ArticleId IdType="pubmed">32807020</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin M., Smolag K.I., Bj&#xf6;rk A., Gullstrand B., Okr&#xf3;j M., Leffler J., J&#xf6;nsen A., Bengtsson A.A., Blom A.M. Plasma C4d as Marker for Lupus Nephritis in Systemic Lupus Erythematosus. Arthritis Res. Ther. 2017;19:266. doi: 10.1186/s13075-017-1470-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-017-1470-2</ArticleId><ArticleId IdType="pmc">PMC5717799</ArticleId><ArticleId IdType="pubmed">29208014</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin M., Trattner R., Nilsson S.C., Bj&#xf6;rk A., Zickert A., Blom A.M., Gunnarsson I. Plasma C4d Correlates with C4d Deposition in Kidneys and With Treatment Response in Lupus Nephritis Patients. Front. Immunol. 2020;11:582737. doi: 10.3389/fimmu.2020.582737.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.582737</ArticleId><ArticleId IdType="pmc">PMC7561717</ArticleId><ArticleId IdType="pubmed">33133102</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimoto Y., Horiuchi T. The Complement System and ANCA Associated Vasculitis in the Era of Anti-Complement Drugs. Front. Immunol. 2022;13:926044. doi: 10.3389/fimmu.2022.926044.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.926044</ArticleId><ArticleId IdType="pmc">PMC9260009</ArticleId><ArticleId IdType="pubmed">35812453</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H., Liu C., Shi B., Zhang Z., Feng R., Guo M., Lu L., Shi S., Gao X., Chen W., et al. Mesenchymal Stem Cells Control Complement C5 Activation by Factor H in Lupus Nephritis. EBioMedicine. 2018;32:21&#x2013;30. doi: 10.1016/j.ebiom.2018.05.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2018.05.034</ArticleId><ArticleId IdType="pmc">PMC6020800</ArticleId><ArticleId IdType="pubmed">29885865</ArticleId></ArticleIdList></Reference><Reference><Citation>Song D., Guo W.Y., Wang F.M., Li Y.Z., Song Y., Yu F., Zhao M.H. Complement Alternative Pathway&#x2019;s Activation in Patients with Lupus Nephritis. Am. J. Med. Sci. 2017;353:247&#x2013;257. doi: 10.1016/j.amjms.2017.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjms.2017.01.005</ArticleId><ArticleId IdType="pubmed">28262211</ArticleId></ArticleIdList></Reference><Reference><Citation>Halkj&#xe6;r L., Troldborg A., Pedersen H., Jensen L., Hansen A.G., Hansen T.K., Bjerre M., &#xd8;stergaard J.A., Thiel S. Complement Receptor 2 Based Immunoassay Measuring Activation of the Complement System at C3-Level in Plasma Samples From Mice and Humans. Front. Immunol. 2020;11:774. doi: 10.3389/fimmu.2020.00774.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00774</ArticleId><ArticleId IdType="pmc">PMC7214740</ArticleId><ArticleId IdType="pubmed">32431705</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzi S., Navratil J.S., Ruffing M.J., Liu C.C., Danchenko N., Nilson S.E., Krishnaswami S., King D.E.S., Kao A.H., Ahearn J.M. Measurement of Erythrocyte C4d and Complement Receptor 1 in Systemic Lupus Erythematosus. Arthritis Rheum. 2004;50:3596&#x2013;3604. doi: 10.1002/art.20561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20561</ArticleId><ArticleId IdType="pubmed">15529364</ArticleId></ArticleIdList></Reference><Reference><Citation>Navratil J.S., Manzi S., Kao A.H., Krishnaswami S., Liu C.C., Ruffing M.J., Shaw P.S., Nilson A.C., Dryden E.R., Johnson J.J., et al. Platelet C4d Is Highly Specific for Systemic Lupus Erythematosus. Arthritis Rheum. 2006;54:670&#x2013;674. doi: 10.1002/art.21627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21627</ArticleId><ArticleId IdType="pubmed">16447243</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.C., Kao A.H., Hawkins D.M., Manzi S., Sattar A., Wilson N., Ahearn J.M. Lymphocyte-Bound Complement Activation Products as Biomarkers for Diagnosis of Systemic Lupus Erythematosus. Clin. Transl. Sci. 2009;2:300&#x2013;308. doi: 10.1111/j.1752-8062.2009.00135.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1752-8062.2009.00135.x</ArticleId><ArticleId IdType="pmc">PMC2790176</ArticleId><ArticleId IdType="pubmed">20161444</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalunian K.C., Chatham W.W., Massarotti E.M., Reyes-Thomas J., Harris C., Furie R.A., Chitkara P., Putterman C., Gross R.L., Somers E.C., et al. Measurement of Cell-Bound Complement Activation Products Enhances Diagnostic Performance in Systemic Lupus Erythematosus. Arthritis Rheum. 2012;64:4040&#x2013;4047. doi: 10.1002/art.34669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34669</ArticleId><ArticleId IdType="pubmed">22932861</ArticleId></ArticleIdList></Reference><Reference><Citation>Mossell J., Goldman J.A., Barken D., Alexander R.V. The Avise Lupus Test and Cell-Bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus. Open Rheumatol. J. 2016;10:71&#x2013;80. doi: 10.2174/1874312901610010071.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1874312901610010071</ArticleId><ArticleId IdType="pmc">PMC5101629</ArticleId><ArticleId IdType="pubmed">27867431</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang E., Taylor M., McMahon M. Utility of the AVISE Connective Tissue Disease Test in Predicting Lupus Diagnosis and Progression. Lupus Sci. Med. 2020;7:e000345. doi: 10.1136/lupus-2019-000345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2019-000345</ArticleId><ArticleId IdType="pmc">PMC7101049</ArticleId><ArticleId IdType="pubmed">32231785</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriens C., Alexander R.V., Narain S., Saxena A., Collins C.E., Wallace D.J., Massarotti E., Conklin J., Kalunian K.C., Putterman C., et al. Cell-Bound Complement Activation Products Associate with Lupus Severity in SLE. Lupus Sci. Med. 2020;7:e000377. doi: 10.1136/lupus-2019-000377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2019-000377</ArticleId><ArticleId IdType="pmc">PMC7228655</ArticleId><ArticleId IdType="pubmed">32371480</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill J.T., Petri M.A., Buyon J., Ramsey-Goldman R., Kalunian K., Putterman C., Conklin J., Furie R.A., Dervieux T. Erythrocyte-Bound C4d in Combination with Complement and Autoantibody Status for the Monitoring of SLE. Lupus Sci. Med. 2018;5:e000263. doi: 10.1136/lupus-2018-000263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000263</ArticleId><ArticleId IdType="pmc">PMC5976122</ArticleId><ArticleId IdType="pubmed">29868177</ArticleId></ArticleIdList></Reference><Reference><Citation>Svenungsson E., Gustafsson J.T., Grosso G., Rossides M., Gunnarsson I., Jensen-Urstad K., Larsson A., Ekdahl K.N., Nilsson B., Bengtsson A.A., et al. Complement Deposition, C4d, on Platelets Is Associated with Vascular Events in Systemic Lupus Erythematosus. Rheumatology. 2020;59:3264&#x2013;3274. doi: 10.1093/rheumatology/keaa092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa092</ArticleId><ArticleId IdType="pmc">PMC7590416</ArticleId><ArticleId IdType="pubmed">32259250</ArticleId></ArticleIdList></Reference><Reference><Citation>Gartshteyn Y., Mor A., Shimbo D., Khalili L., Kapoor T., Geraldino-Pardilla L., Alexander R.V., Conklin J., Dervieux T., Askanase A.D. Platelet Bound Complement Split Product (PC4d) Is a Marker of Platelet Activation and Arterial Vascular Events in Systemic Lupus Erythematosus. Clin. Immunol. 2021;228:108755. doi: 10.1016/j.clim.2021.108755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2021.108755</ArticleId><ArticleId IdType="pmc">PMC8252918</ArticleId><ArticleId IdType="pubmed">33984497</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M.A., Conklin J., O&#x2019;Malley T., Dervieux T. Platelet-Bound C4d, Low C3 and Lupus Anticoagulant Associate with Thrombosis in SLE. Lupus Sci. Med. 2019;6:6&#x2013;11. doi: 10.1136/lupus-2019-000318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2019-000318</ArticleId><ArticleId IdType="pmc">PMC6519690</ArticleId><ArticleId IdType="pubmed">31168401</ArticleId></ArticleIdList></Reference><Reference><Citation>Drachenberg C.B., Papadimitriou J.C., Chandra P., Haririan A., Mendley S., Weir M.R., Rubin M.F. Epidemiology and Pathophysiology of Glomerular C4d Staining in Native Kidney Biopsies. Kidney Int. Rep. 2019;4:1555&#x2013;1567. doi: 10.1016/j.ekir.2019.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2019.07.015</ArticleId><ArticleId IdType="pmc">PMC6933466</ArticleId><ArticleId IdType="pubmed">31890997</ArticleId></ArticleIdList></Reference><Reference><Citation>Loupy A., Haas M., Roufosse C., Naesens M., Adam B., Afrouzian M., Akalin E., Alachkar N., Bagnasco S., Becker J.U., et al. The Banff 2019 Kidney Meeting Report (I): Updates on and Clarification of Criteria for T Cell&#x2013; and Antibody-Mediated Rejection. Am. J. Transplant. 2020;20:2318&#x2013;2331. doi: 10.1111/ajt.15898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.15898</ArticleId><ArticleId IdType="pmc">PMC7496245</ArticleId><ArticleId IdType="pubmed">32463180</ArticleId></ArticleIdList></Reference><Reference><Citation>Allam M., Fathy H., Allah D.A., Salem M.A.E. Lupus Nephritis: Correlation of Immunohistochemical Expression of C4d, CD163-Positive M2c-like Macrophages and Foxp3-Expressing Regulatory T Cells with Disease Activity and Chronicity. Lupus. 2020;29:943&#x2013;953. doi: 10.1177/0961203320932663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320932663</ArticleId><ArticleId IdType="pubmed">32580679</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Y., Yu X., Wu L., Tan Y., Qu Z., Yu F. The Spectrum of C4d Deposition in Renal Biopsies of Lupus Nephritis Patients. Front. Immunol. 2021;12:654652. doi: 10.3389/fimmu.2021.654652.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.654652</ArticleId><ArticleId IdType="pmc">PMC8281350</ArticleId><ArticleId IdType="pubmed">34276649</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>